Printer Friendly

COHERENT TO BEGIN CLINICAL TRIALS ON LASER LITHOTRIPSY

 COHERENT TO BEGIN CLINICAL TRIALS ON LASER LITHOTRIPSY
 PALO ALTO, Calif., June 17 /PRNewswire/ -- Coherent Inc.


(NASDAQ: COHR) announced today that it received clearance from the FDA to begin human trials on the use of the VersaPulse surgical laser for the treatment of urinary stones. This minimally invasive procedure involves using an endoscope and the laser to fragment urinary stones in the ureter. Stones located in the lower third of the ureter cannot be treated with extracorporeal shock wave lithotripsy.
 Clinical trials will be conducted at four sites -- the University of California in San Francisco; St. Vincent's Hospital in Erie, Pa.; Shelby Medical Center in Shelby, Ala.; and Jefferson University Medical Center in Philadelphia.
 Dr. Douglas Johnson, professor of urology at the University of Texas at Houston who conducted the initial animal studies of the VersaPulse laser on urologic soft tissue and on lithotripsy, stated that, "although the results of our investigation are preliminary, we believe that this laser will become the urologists' laser of the future."
 According to Ted Belleza, director of marketing at Coherent, this latest development, together with the recent FDA approval for the use of the VersaPulse laser on soft tissue in urology, is a significant step toward Coherent's goal of providing the urologist with a single laser for all urologic applications, such as bladder tumors and urethral and ureteral strictures.
 The VersaPulse laser has been cleared for use in several other surgical applications. These include arthroscopic surgery of the knee, shoulder, elbow, ankle, wrist, and temporomandibular joint, percutaneous discectomy for the treatment of low back pain, and open and endoscopic general surgery. Other applications pending FDA clearance include intra-abdominal gynecologic surgery, endoscopic sinus surgery, and ophthalmic surgery.
 Coherent Inc. is recognized as a world leader in the design, manufacture and marketing of lasers and laser systems for medicine, science and industry. Please direct any questions to Robert J. Quillinan, vice president and chief financial officer at 415-852-8268.
 -0- 6/17/92
 /CONTACT: Robert J. Quillinan of Coherent Inc., 415-852-8268/
 (COHR) CO: Coherent Inc. ST: California IN: MTC SU:


JL -- SJ004 -- 1134 06/17/92 14:07 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1992
Words:352
Previous Article:SUPERIOR ENVIRONMENTAL CORP. FORMS PARTNERSHIP WITH ROGERS HIGH SCHOOL
Next Article:SC BANCORP ELECTS NEW LEADERSHIP
Topics:


Related Articles
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
FDA CLEARS LASER FOR TREATMENT OF UROLOGIC DISORDERS
LASER CLEARED FOR ENDONASAL PROCEDURES
CLINICAL TRIALS EXPANDED FOR TRANSMYOCARDIAL REVASCULARIZATION SURGICAL PROCEDURE FOR HEART PATIENTS
SUMMIT TECHNOLOGY RECEIVES TWO FDA APPROVALS TO BEGIN PHASE III CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS & ASTIGMATISM
COHERENT INC. ANNOUNCES UROLOGY PROCEDURE APPROVED IN JAPAN
AUTONOMOUS TECHNOLOGIES CORPORATION RECEIVES FDA IDE APPROVAL TO BEGIN US CLINICAL TRIALS FOR LASER VISION CORRECTION
COHERENT, INC. RECEIVES FDA CLEARANCE FOR DERMATOLOGICAL LASER

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters